| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
This major strategic analysis provides a detailed insight into the current and
future market for nucleic acid drug delivery technology.
Providing...
Critical analyses and competitive ratings for major specialist developers
Unique sales forecasts to 2015 for key current and new products utilising
nucleic acid drug delivery technologies A comprehensive examination of this
major drug delivery sector
Although the nucleic acid delivery market is still in its infancy there are
currently 1,300 clinical trials underway worldwide. The majority of these are
in early clinical development (c. 67%) with just over 2% on Phase II trials.
This indicates that relatively few nucleic acid candidates are likely to reach
the market in the short term but the potential of the sector is significant.
Our market analysis indicates that relatively few nucleic acid based products
have been approved for human prescription. Those that have, rely on novel
delivery technologies. The report estimates the nucleic acid market is worth
around US$65 million globally in 2007.
By 2015, nucleic acid products in development from ten key companies could
generate additional sales of around US$1.1 billion. These products utilise a
range of delivery platforms including viral to non-viral delivery systems and
cover gene therapies, gene agents and DNA vaccines for a variety of targets
including cancer, cardiovascular disease and infectious diseases.
Drivers and dampeners of growth
The future of nucleic acid based therapies and gene therapies hangs in the
balance whilst regulators and researchers weigh up the unmet clinical need for
curative/preventative therapies versus the safety issues (immunogenicity,
pathogenicity) associated with the delivery of some of these agents.
Whilst the majority of gene therapy trials under evaluation incorporate the
use of viral vectors there has been a shift in opinion in favour of non-viral
delivery. However, significant opportunities exist for future commercial
development within the pharmaceutical industry. These include:
- Development of new polymers and biopolymers that may be utilised in the
safe and efficient delivery of genetic material to host cells
- The development of viral and non-viral vectors that can be regulated and
incorporate high DNA payloads
- Targeted delivery of nucleic acid drugs to increase the specificity of
treatment
- Cost-effective production and application of safe and efficient vectors
for the delivery of nucleic acid-based therapies
- Identification and delivery of polygenic genes for the treatment of
multi-gene based diseases e.g. cancer
- Improvements in DNA vaccine delivery and immune stimulation
Which companies and products will succeed in the nucleic acid delivery sector?
What technical and regulatory hurdles must they overcome? This volume will
tell you!
TABLE OF CONTENTS
Executive Summary
- Competitor Ratio Analysis Summary
Introduction
Overview of delivery technologies for genetic material: past, prese nt & future
- Nucleic acid delivery: motivators & resistors
NUCLEIC ACID DELIVERY TECHNOLOGIES
- Types of nucleic acid based products under development by the pharma
industry
- Viral vector delivery of nucleic acids
- Figure 1: Schematic of gene therapy utilising an AAV vector
- Figure 2: Schematic of gene therapy utilising HVJ envelope - virosome
- Non-viral vector delivery of nucleic acids
- Figure 3: Stable nucleic acid-lipid particles
- Figure 4: Targeted nanoparticles
- Figure 5: Schematic of Macroflux Technology
- Figure 6: Schematic of PMED Technology and delivery
- Table 1: Advantages and disadvantages of nucleic acid platforms
- Current therapeutic applications for the viral and non-viral delivery of
nucleic acids
- Leading nucleic acid based products in development
- Table 2: Nucleic acid-based approved/filed drugs
- Table 3: Selection of nucleic acid-based developmental drugs
- Future commercial applications & opportunities
STRAT EGIES OF DRUG DELIVERY COMPANIES
- Leading nucleic acid drug delivery companies
- Table 4: Leading nucleic acid drug delivery specialists
- Partnerships & acquisitions
- Strategic developmental & commercialisation partnerships
- Mergers & acquisitions
- Table 5: Recent partnerships & acquisitions in the nucleic acid field
- Intellectual Property
- Table 6: Nucleic acid patents
THE viral and non-viral vector Delivery MARKET
- Now 2007
- Table 7: Approved nucleic acid product sales
- Future 2015
- Table 8: Global controlled-release product sales
- Table 9: Novel nucleic acid product sales
COMPETITOR ANALYSIS
- Movers & Shakers: Cutting edge or losing their grip
- Table 10: Movers & shakers in nucleic acid drug delivery systems
COMPANY PROFILES
- AlphaVax, Inc.
- Figure 7: The alphavaccine platform system
- Table 11: AlphaVax product pipeline
- Table 12: AlphaVax' sales forecasts (US$ million)
- Altea Therapeutics, Inc.)
- Table 13: Altea Therapeutics' product pipeline
- AP Pharma, Inc
- Table 14: AP Pharma's product pipeline
- Aradigm, Inc
- Table 15: Aradigm's product pipeline
- BioDelivery Sciences International
- Figure 8: Bioral Technology
- Figure 9: Direct membrane fusion
- Table 16: BDSI's product pipeline
- Calando Pharmaceuticals
- Figure 10: Schematic of cyclodextrin polymeric nanoparticles
- Table 17: Calando's product pipeline
- Table 18: Calando's sales forecasts
- Copernicus Therapeutics
- Figure 11: Uptake and trafficking of condensed nanoparticle DNA
- Table 19: Copernicus' product pipeline
- Table 20: Copernicus' sales forecasts
- Diatos SA
- Table 21: Diatos' product pipeline
- DOR BioPharma, Inc
- Table 22: DOR's product pipeline
- Expression Genetics, Inc
- Figure 12: TheraPlas Technology Platform
- Table 23: EGEN's product pipeline
- Table 24: EGEN's sales forecasts
- Inovio Biomedical Corporation
- Figure 13: Inovio's gene delivery platform
- Table 25: Inovio's product pipeline
- Table 26: Inovio's sales forecasts
- Macroflux Corporation
- Table 27: Macroflux' product pipeline
- Maxcyte, Inc
- Figure 14: MaxCyte's GT ex-vivo cell loading system
- Table 28: MaxCyte's product pipeline
- Mirus Bio Corporation
- Figure 15: PolyConjugates - siRNA delivery system
- Table 29: Mirus' product pipeline
- Table 30: Mirus' sales forecasts
- Nanotherapeutics Inc.
- Table 31: Nanotherapeutics' product pipeline
- NeoPharm
- Table 32: NeoPharm's product pipeline
- Novagali Pharma SA
- Table 33: Novagali's product pipeline
- PCI Biotech
- Table 34: PCI's product pipeline
- PowderMed Inc
- Table 35: PowderMed's product pipeline
- Table 5.2.25: PowderMed's sales forecasts
- Protiva Biotherapeutics, Inc
- Table 37: Protiva's product pipeline
- Table 38: Protiva's sales forecasts
- Silence Therapeutics plc
- Table 39: Silence Therapeutics' product pipeline
- Table 40: Silence Therapeutics' sales forecasts
- Supratek Pharma Inc.
- Table 40: Supratek's product pipeline
- Tekmira Pharmaceuticals Corporation
- Table 42: Tekmira's product pipeline
- Table 43: Tekmira's sales forecasts
- Vical Inc.
- Table 44: Vical's product pipeline
- Table 45: Vical's sales forecasts
APENDIX 1
- Table 46: Global nucleic acid approved drugs sales 2006A-20015E
APPENDIX 2
- Table 47: Global nucleic acid developmental drugs sales 2006A-20015E
APENDIX 3
- Competitor Ratio Analysis Criteria
- Table 48: Key nucleic acid delivery companies by 2015
BIBLIOGRAPHY
GLOSSARY
ACRONYMS
FOOTNOTE REFERENCES
|
